-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
IndexIQ Advisors LLC Makes New Investment in Silverback Therapeutics, Inc. (NASDAQ:SBTX)
IndexIQ Advisors LLC Makes New Investment in Silverback Therapeutics, Inc. (NASDAQ:SBTX)
IndexIQ Advisors LLC bought a new position in Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Rating) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 113,499 shares of the company's stock, valued at approximately $398,000. IndexIQ Advisors LLC owned approximately 0.32% of Silverback Therapeutics at the end of the most recent quarter.
Several other hedge funds also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC acquired a new position in shares of Silverback Therapeutics in the 1st quarter worth approximately $142,000. Woodline Partners LP grew its position in shares of Silverback Therapeutics by 16.1% in the 4th quarter. Woodline Partners LP now owns 493,895 shares of the company's stock worth $3,289,000 after acquiring an additional 68,634 shares in the last quarter. Wasatch Advisors Inc. grew its position in shares of Silverback Therapeutics by 23.9% in the 4th quarter. Wasatch Advisors Inc. now owns 1,773,690 shares of the company's stock worth $11,813,000 after acquiring an additional 341,762 shares in the last quarter. Nextech Invest AG acquired a new position in shares of Silverback Therapeutics in the 4th quarter worth approximately $12,721,000. Finally, GSA Capital Partners LLP acquired a new position in shares of Silverback Therapeutics in the 4th quarter worth approximately $77,000. Institutional investors and hedge funds own 85.98% of the company's stock.
Get Silverback Therapeutics alerts:Wall Street Analysts Forecast Growth
Separately, Stifel Nicolaus decreased their target price on Silverback Therapeutics from $6.00 to $5.00 in a research report on Friday, May 13th. Five research analysts have rated the stock with a hold rating, According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $33.00.
Silverback Therapeutics Price Performance
NASDAQ:SBTX opened at $4.81 on Wednesday. Silverback Therapeutics, Inc. has a 12-month low of $2.80 and a 12-month high of $31.72. The firm has a market capitalization of $169.05 million, a P/E ratio of -1.77 and a beta of 0.64. The business has a 50 day simple moving average of $4.35 and a 200 day simple moving average of $3.92.Silverback Therapeutics (NASDAQ:SBTX – Get Rating) last released its quarterly earnings data on Thursday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.03). Research analysts anticipate that Silverback Therapeutics, Inc. will post -2.23 EPS for the current fiscal year.
Silverback Therapeutics Company Profile
(Get Rating)
Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.
Read More
- Get a free copy of the StockNews.com research report on Silverback Therapeutics (SBTX)
- Are 3M, Honeywell, GE Buys After Quarterly Reports?
- This Defense Stock Has Bullish Fundamentals AND Technicals
- Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
- CVS and Walgreens Show Why Investment Objectives Matter
- Are Medtronic And Intuitive Surgical Poised For Big Growth?
Want to see what other hedge funds are holding SBTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Rating).
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
IndexIQ Advisors LLC bought a new position in Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Rating) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 113,499 shares of the company's stock, valued at approximately $398,000. IndexIQ Advisors LLC owned approximately 0.32% of Silverback Therapeutics at the end of the most recent quarter.
根據IndexIQ Advisors LLC在第一季度購買了Silverback治療公司(納斯達克：SBTX-GET評級)的新頭寸，該公司在最近提交給美國證券交易委員會的文件中稱。該公司購買了113,499股該公司股票，價值約39.8萬美元。截至最近一個季度末，IndexIQ Advisors LLC擁有Silverback Treeutics公司約0.32%的股份。
Several other hedge funds also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC acquired a new position in shares of Silverback Therapeutics in the 1st quarter worth approximately $142,000. Woodline Partners LP grew its position in shares of Silverback Therapeutics by 16.1% in the 4th quarter. Woodline Partners LP now owns 493,895 shares of the company's stock worth $3,289,000 after acquiring an additional 68,634 shares in the last quarter. Wasatch Advisors Inc. grew its position in shares of Silverback Therapeutics by 23.9% in the 4th quarter. Wasatch Advisors Inc. now owns 1,773,690 shares of the company's stock worth $11,813,000 after acquiring an additional 341,762 shares in the last quarter. Nextech Invest AG acquired a new position in shares of Silverback Therapeutics in the 4th quarter worth approximately $12,721,000. Finally, GSA Capital Partners LLP acquired a new position in shares of Silverback Therapeutics in the 4th quarter worth approximately $77,000. Institutional investors and hedge funds own 85.98% of the company's stock.
其他幾家對衝基金最近也調整了在該公司的頭寸。AllSpring Global Investments Holdings LLC在第一季度收購了Silverback Treeutics公司的新股票，價值約14.2萬美元。Woodline Partners LP在第四季度將其在Silverback Treateutics的股票頭寸增加了16.1%。Woodline Partners LP現在擁有493,895股該公司股票，價值3,289,000美元，上個季度又購買了68,634股。Wasatch Advisors Inc.在第四季度將其在Silverback Treateutics的股票頭寸增加了23.9%。Wasatch Advisors Inc.在上個季度增持了341,762股後，現在持有1,773,690股該公司股票，價值11,813,000美元。NeXTech Invest AG在第四季度收購了Silverback Treeutics的新股票，價值約12,721,000美元。最後，GSA Capital Partners LLP在第四季度收購了Silverback Treeutics公司的新股票，價值約7.7萬美元。機構投資者和對衝基金持有該公司85.98%的股票。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
Separately, Stifel Nicolaus decreased their target price on Silverback Therapeutics from $6.00 to $5.00 in a research report on Friday, May 13th. Five research analysts have rated the stock with a hold rating, According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $33.00.
另外，Stifel Nicolaus在5月13日星期五的一份研究報告中將Silverback Treeutics的目標價格從6.00美元下調至5.00美元。根據MarketBeat.com的數據，五位研究分析師對該股的評級為持有，共識評級為持有，共識目標價為33.00美元。
Silverback Therapeutics Price Performance
銀背療法的價格表現
Silverback Therapeutics (NASDAQ:SBTX – Get Rating) last released its quarterly earnings data on Thursday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.03). Research analysts anticipate that Silverback Therapeutics, Inc. will post -2.23 EPS for the current fiscal year.
銀背治療公司(納斯達克代碼：SBTX-GET Rating)最近一次發佈季度收益數據是在5月12日星期四。該公司公佈本季度每股收益(EPS)為0.70美元，低於分析師一致預期的0.67美元和0.03美元。研究分析師預計，銀背治療公司本會計年度的每股收益將達到2.23美元。
Silverback Therapeutics Company Profile
銀背治療公司簡介
(Get Rating)
(獲取評級)
Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.
Silverback Treateutics，Inc.是一家生物製藥公司，開發組織靶向療法，用於治療慢性病毒感染、癌症和其他嚴重疾病。該公司提供SBT8230來治療慢性乙肝病毒感染，方法是通過靶向肝臟的TLR8激活來激發抗病毒免疫反應。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on Silverback Therapeutics (SBTX)
- Are 3M, Honeywell, GE Buys After Quarterly Reports?
- This Defense Stock Has Bullish Fundamentals AND Technicals
- Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
- CVS and Walgreens Show Why Investment Objectives Matter
- Are Medtronic And Intuitive Surgical Poised For Big Growth?
- 免費獲取StockNews.com關於銀背療法(SBTX)的研究報告
- 3M、霍尼韋爾、通用電氣在季度報告後收購嗎？
- 這隻國防股票的基本面和技術面都看漲
- 索菲金融股票終於準備好為投資者買單了嗎？
- CVS和Walgreens展示為什麼投資目標很重要
- 美敦力和直覺外科公司準備實現大增長嗎？
Want to see what other hedge funds are holding SBTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Rating).
想看看其他對衝基金持有SBTX的情況嗎？訪問HoldingsChannel.com獲取銀背治療公司(納斯達克代碼：SBTX-GET Rating)的最新13F備案文件和內幕交易信息。
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《銀背治療日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Silverback Treeutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧